Method of preparing a latanoprost ophthalmic solution and resulting solution

Abstract

A method of solubilizing an analog active agent of the prostaglandin F2α, such as latanoprost, is described and a method of preparing an ophthalmic solution of the solubilized latanoprost for the treatment of distinct ocular ailments. This invention also refers to an ophthalmic aqueous solution resulting from the aforementioned method, which is characterized by its chemical stability at room temperature, its safety, and innocuousness and efficiency in the treatment of the patient. The new ophthalmic aqueous solution is distinguished because its pharmaceutical value is found in the handling of a vehicle of easy access that not only permits the solubility of latanoprost, but also promotes its chemical stability and a greater tolerance of the patient with its ophthalmic application for the treatment of the patient's ailment.

1 - 9 . (canceled) 
     
     
         10 . A method for the treatment of patients with ailments of the eye, which consists in administering an adequate therapeutic amount, to the eye of a patient, of an aqueous solution that includes an analog of prostaglandin F2α. 
     
     
         11 . The method of  claim 10 , in which the analog of the prostaglandin F2α is latanoprost. 
     
     
         12 . The method of  claim 10 , in which the concentration of latanoprost in the solution is of 0.005%.